
    
      The proportion of HCV infected patients over age 65 years in Western countries is increasing.
      This growth and the advent of new antiviral therapy bring into the question the real world
      efficacy and safety of the combination of Sofosbuvir and Simeprevir (SOF/SMV) plus a flat
      dose of ribavirin (RBV) in elderly patients (Group II) compared to younger patients (Group I)
      Multicenter, real world investigation study of once daily treatment with SOF 400 mg + SMV 150
      mg with a flat dose of RBV 800 mg/day for a duration of 12 weeks in treatment na√Øve or
      experienced HCV genotype 1-infected patients with compensated cirrhosis.To evaluate efficacy,
      tollerability and safety of SOF/SMV/RBV in two different Group of patients.
    
  